Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.
The study was published Dec. 10 in the Journal of Clinical Oncology.
"Our analysis shows that optimal therapy for younger and older patients with chronic lymphocytic leukemia is likely to be different, at least when using current treatments," says first author Dr. Jennifer Woyach, assistant professor of hematology at the OSUCCC – James.
"We hope this study will shape future research by highlighting the importance of enrolling older patients on clinical trials and of developing trials that specifically target older patients."
Doctors diagnose about 15,000 new cases of chronic lymphocytic leukemia (CLL) annually in the United States, making it the most common form of leukemia. It remains incurable, and about 4,400 Americans die of the malignancy each year. CLL most often occurs in people older than age 65; the average age at diagnosis is 72. Yet, most
CLL clinical-trial participants are in their early 60s.
"Our findings apply to both routine care of CLL patients 70 years and older and to future CLL trials," says principal investigator Dr. John Byrd, a CLL specialist and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC – James.
"The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age," says Byrd, who is the D. Warren Brown Designated Chair in Leukemia Research.
"These data also show that future treatment trials for older adults with CLL should build on CD20 antibody therapies such as rituximab and ofatumumab, but not on fludarabine or alemtuzumab."
Byrd, Woyach and their colleagues reviewed 663 CLL patients who were enrolled in four sequential CLL clinical trials evaluating front-line therapies. The researchers looked for differences in treatment outcomes between older and younger patients to identify the most effective therapy for older adults.
The four trials, all sponsored by the Cancer and Leukemia Group B (CALGB) clinical cooperative group, compared these treatments: chlorambucil versus fludarabine, fludarabine plus rituximab versus fludarabine, fludarabine with consolidation alemtuzumab, and fludarabine plus rituximab with consolidation alemtuzumab.
Key conclusions include:
Ohio State University Medical Center: http://medicalcenter.osu.edu/Pages/index.aspx
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Treating patients with the deadly Ebola virus takes doctors, drugs, and a whole lot of chlorine.
For decades, smokers in eastern Europe have used cytisine from laburnum trees to help them quit. Good results in a new trial could make cytisine much more popular
The National Institutes of Health has approved requests for waivers from a moratorium on experiments that aim to make the virus that causes Middle East respiratory syndrome more infectious in mice.
It's all fun and games until someone dislocates a knee, wets himself or has a stroke
Use of synthetic drugs, like bath salts, by young people continues to decline across the nation, according to a study by the University of Michigan.
Researchers are struggling with how to balance the benefits and risks of genetic experiments that can give viruses new talents for causing infections.
For all the medicine they provide at this center, physicians and staff from Doctors Without Borders spend as much time encouraging the patients to eat, drink, and keep fighting. Every patient gets a standard regimen of antibiotics, paracetemol and other pain medications, vitamins, oral rehydration therapy or intravenous fluids. Drugs can control nausea for those who need them; everyone gets antimalarials.
Dengue sickens millions of people each year, and there's no cure. Now scientists have found powerful antibodies that stop the virus. Their discovery offers a road map to develop a simple vaccine.
British doctors make the case for playing music during an operation
Doughnuts? No thank you. An edible powder made from stuff our gut bacteria excrete can stop people gaining weight when taken daily